Immuno-Oncology | Specialty

Frontline Pembrolizumab Regimen Approved in Europe for Squamous NSCLC

March 14th 2019

The European Commission has approved pembrolizumab in combination with carboplatin and either paclitaxel or nab-paclitaxel for the frontline treatment of patients with metastatic squamous non–small cell lung cancer.

Rizvi Highlights Impact of Immunotherapy and Next Steps NSCLC

March 12th 2019

Naiyer A. Rizvi, MD, highlights the progress made with immunotherapy in patients with NSCLC and shed light on where further research needs to go to move the needle forward.

Dr. Naidoo on Considerations for Managing irAEs in NSCLC

March 11th 2019

Jarushka Naidoo, MBBCh, assistant professor of oncology, Johns Hopkins University, discusses considerations for managing immune-related adverse events in patients with non–small cell lung cancer.

Dr. Powles on Rationale for KEYNOTE-426 in mRCC

March 11th 2019

Thomas Powles, MBBS, MRCP, MD, director, Barts Cancer Institute, discusses the rationale for the KEYNOTE-426 study in patients with metastatic renal cell carcinoma.

Pembrolizumab Plus Lenvatinib Elicits Responses in Urothelial Cancer

March 11th 2019

Combining lenvatinib and pembrolizumab led to a 25% overall response rate in patients with urothelial carcinoma and was associated with a manageable safety profile.

Dr. Mittendorf on FDA Approval of Frontline Atezolizumab/Nab-Paclitaxel in PD-L1+ TNBC

March 9th 2019

Elizabeth A. Mittendorf, MD, PhD, director of the Breast Immuno-Oncology Program at Dana-Farber/Brigham and Women's Cancer Center, discusses the frontline approval of atezolizumab in combination with nab-paclitaxel in patients with locally advanced or metastatic PD-L1

Frontline Atezolizumab Regimen Approved in Europe for NSCLC

March 8th 2019

The European Commission has approved and granted marketing authorization to the frontline combination of atezolizumab, bevacizumab, paclitaxel, and carboplatin for the first-line treatment of patients with metastatic, nonsquamous non–small cell lung cancer.

Study Exclusion Criteria Limits Real-World Benefit of Immunotherapy in Lung Cancer

March 6th 2019

Mohammad Jahanzeb, MD, shares the challenges of real-world eligibility for immunotherapy in lung cancer and beyond.

Panel Proposes Standards for Reporting Data From Immuno-Oncology Trials

March 6th 2019

The standards for reporting findings from immunotherapy studies should reflect the unique efficacy and toxicity characteristics of this rapidily emerging modality, with detailed and transparent explanations of definitions.

Dr. Balar Discusses KEYNOTE-057 Study in NMIBC

March 6th 2019

Arjun V. Balar, MD, assistant professor, Department of Medicine, director, Genitourinary Medical Oncology Program, NYU Langone’s Perlmutter Cancer Center, discusses findings from the KEYNOTE-057 study presented at the 2019 Genitourinary Cancers Symposium.

Dr. Jahanzeb on Immunotherapy in Elderly Patients With NSCLC

March 1st 2019

Mohammad Jahanzeb, MD, professor of clinical medicine, Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses immunotherapy in the treatment of elderly patients with non–small cell lung cancer.

Dr. Concepcion on Potential for Immunotherapy in CRPC

February 27th 2019

Raoul S. Concepcion, MD, FACP, director, Comprehensive Prostate Center, discusses the potential for immunotherapy in the treatment of patients with castration-resistant prostate cancer.

A Game-Changing Year for NSCLC

February 26th 2019

Available Therapies for ALK-Rearranged NSCLC

February 26th 2019

Resistance Mechanisms in EGFR+ NSCLC

February 26th 2019

Osimertinib, the Standard for EGFR+ NSCLC

February 26th 2019

Molecular Testing for NSCLC in 2019

February 26th 2019

ADRIATIC Trial in Locally Advanced Small-Cell Lung Cancer

February 26th 2019

A Win for Small-Cell Lung Cancer: IMPOWER 133

February 26th 2019

Treatment Options for mNSCLC After Progression

February 26th 2019